CTI BioPharma Corp. (CTIC) Short Interest Down 23.5% in August
CTI BioPharma Corp. (NASDAQ:CTIC) was the recipient of a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 437,540 shares, a decrease of 23.5% from the August 15th total of 571,837 shares. Approximately 1.1% of the company’s stock are sold short. Based on an average trading volume of 129,982 shares, the days-to-cover ratio is presently 3.4 days.
CTI BioPharma Corp. (NASDAQ CTIC) opened at 3.32 on Friday. The stock’s market cap is $105.33 million. The firm has a 50-day moving average price of $3.34 and a 200-day moving average price of $3.76. CTI BioPharma Corp. has a 12-month low of $0.36 and a 12-month high of $6.48.
CTI BioPharma Corp. (NASDAQ:CTIC) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $0.03 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.60) by $0.63. CTI BioPharma Corp. had a negative return on equity of 418.99% and a negative net margin of 136.76%. The business had revenue of $22.23 million for the quarter. Analysts forecast that CTI BioPharma Corp. will post ($1.26) EPS for the current fiscal year.
Separately, Jefferies Group LLC started coverage on CTI BioPharma Corp. in a report on Tuesday, September 12th. They issued a “buy” rating and a $7.50 price target for the company.
Several hedge funds have recently modified their holdings of the stock. Segantii Capital Management Ltd bought a new position in shares of CTI BioPharma Corp. in the 1st quarter valued at approximately $102,000. WASHINGTON TRUST Co bought a new position in shares of CTI BioPharma Corp. in the 2nd quarter valued at approximately $104,000. Acadian Asset Management LLC bought a new position in shares of CTI BioPharma Corp. in the 1st quarter valued at approximately $181,000. Finally, Stonepine Capital Management LLC bought a new position in shares of CTI BioPharma Corp. in the 2nd quarter valued at approximately $7,561,000. 42.87% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “CTI BioPharma Corp. (CTIC) Short Interest Down 23.5% in August” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/17/cti-biopharma-corp-ctic-short-interest-down-23-5-in-august.html.
CTI BioPharma Corp. Company Profile
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Receive News & Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related companies with MarketBeat.com's FREE daily email newsletter.